The Goldman Consensus statement on depression in multiple sclerosis.
about
Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of NeurologyNeuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depressionPsychopathology in multiple sclerosis: diagnosis, prevalence and treatmentAdherence to interferon β-1b treatment in patients with multiple sclerosis in SpainReview of intervention studies on depression in persons with multiple sclerosis.Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis.A tutorial on structural equation modeling for analysis of overlapping symptoms in co-occurring conditions using MPlus.Reliability of regression-based normative data for the oral symbol digit modalities test: an evaluation of demographic influences, construct validity, and impairment classification rates in multiple sclerosis samples.Cardiovascular Dysfunction in Multiple Sclerosis.Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United StatesA computer-based screening method for distress in patients with multiple sclerosis: a feasibility studyThe Mental Health Needs of Individuals Living With Multiple Sclerosis: Implications for Occupational Therapy Practice and Research.Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial.Quality of life in multiple sclerosis.Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance.Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis.Use of health services in people with multiple sclerosis with and without depressive symptoms: a two-year prospective study.Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.Comorbidity increases the risk of hospitalizations in multiple sclerosis.A 10-year population-based study of people with multiple sclerosis in Stockholm, Sweden: use of and satisfaction with care and the value of different factors in predicting use of careIs disability pension a risk indicator for future need of psychiatric healthcare or suicidal behavior among MS patients- a nationwide register study in Sweden?The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trialA population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence.Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations.Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis.Neuropsychiatric manifestations of multiple sclerosis.Depression in multiple sclerosis: a longitudinal analysisTreatment of neuropsychiatric conditions associated with multiple sclerosis.The Gap in the Current Research on the Link between Health Locus of Control and Multiple Sclerosis: Lessons and Insights from a Systematic Review.Variations in and predictors of the occurrence of depressive symptoms and mood symptoms in multiple sclerosis: a longitudinal two-year studyDepression and immunity: inflammation and depressive symptoms in multiple sclerosis.Disentangling Multiple Sclerosis and depression: an adjusted depression screening score for patient-centered careHealth-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidityPsychiatric issues in multiple sclerosis.Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.Major depression and multiple sclerosis - a case reportSetting the agenda for multiple sclerosis rehabilitation research.
P2860
Q24615757-4CFD201C-C4DF-408A-AED3-BA80711B2A70Q28220405-5E94E86B-E355-4AC2-AFBC-6D6DD7BE4A99Q28301691-97173072-A0F0-44EF-A1D9-F9097EEB0E52Q28729921-B1B5581E-DCFA-4905-89E5-23A98F7FF0C1Q30542657-41375C5F-2396-4233-8C50-C21A5E9D30B8Q30564263-C18B351B-8D93-4A08-BC54-A55698141ACDQ30666585-4E14B7A9-C2DD-445B-8FDC-D50B2861F30FQ30736446-8CC50837-CA69-428C-8B46-45753E08FCF9Q33572376-B544DD2F-8ED9-42A3-B1BC-A1061431A6EBQ33659848-BABBA5F3-BE5B-4333-BD66-1AFC046B3F5FQ33807826-4851B52D-AACA-47D1-B31B-3581A0998DF8Q34307014-A63CB2CD-08FB-4A9C-B5FF-7476AF7FE428Q34411269-30891E84-7920-4FC3-82A0-B3ADEEE95995Q34481312-59157B94-D18B-4D51-BC62-CC34EECD2125Q34578783-3F267377-6232-4E27-AA02-BD896398B79FQ34656844-C7AE2E21-C2EC-4D10-9E49-D77BD41515BCQ34656851-98AB703F-BEE6-4D7A-AD57-D6AD34CBE507Q34978960-72B766A2-87E5-41E0-AC30-15EB1CA67873Q35001445-F3BF2A4A-2D22-4550-877F-8D3C15F5B419Q35018491-EAB00EB0-6ABC-4F9A-ABAF-BD1B9321A58BQ35065539-1D18422F-209D-4B0D-B61B-08294DCB6159Q35106304-09DA8BB5-2EE4-45D4-A6CA-7773B3AF474EQ35820929-28EF375D-F141-4A09-9854-F7839E32373FQ35842934-F0699A00-B5CA-431B-B281-0A73CB2E4BD9Q35891823-A4D798A5-8F49-4C77-B028-CDF3EF5CF709Q36227300-2933BD3F-FD98-40D2-9827-AE532B4F0F9DQ36337359-1CE520C5-EDA0-46FB-A27F-7BCBEF95AA0AQ36358378-0CC00748-0B15-4E2C-8712-2B4B5064E021Q36474339-08516AC2-19B3-45B2-A284-9499EA44DD7BQ36585597-A5A63BB6-8313-4A9F-A8A6-7F824E45A5C7Q36641533-23EF6573-0BF1-46D9-8E39-CD2409465539Q36651308-D59EC79A-12F4-4065-A6DE-50BBF0CB6CF8Q36654417-87A2D8AB-1807-49BD-A86A-E8EFFF511093Q36764298-F524257D-4E17-45FB-9728-41FDC0C1A83FQ36776446-C5CA4A45-C2A5-4629-87D1-F5537D269D97Q36796471-35E95EFE-3FDC-4D77-ACE4-646516D3F93AQ36972200-CF88314A-9D52-4252-A455-E623ADC04381Q37056725-6142C0AA-3BEE-433F-8AD2-1F37A6A92580Q37206185-869D7FD6-06E7-426B-A4A4-C685C6B2CFC6Q37218584-0DD7969A-8F39-47F0-A9BA-6EFC392AAB87
P2860
The Goldman Consensus statement on depression in multiple sclerosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The Goldman Consensus statement on depression in multiple sclerosis.
@ast
The Goldman Consensus statement on depression in multiple sclerosis.
@en
type
label
The Goldman Consensus statement on depression in multiple sclerosis.
@ast
The Goldman Consensus statement on depression in multiple sclerosis.
@en
prefLabel
The Goldman Consensus statement on depression in multiple sclerosis.
@ast
The Goldman Consensus statement on depression in multiple sclerosis.
@en
P2860
P1476
The Goldman Consensus statement on depression in multiple sclerosis.
@en
P2093
Goldman Consensus Group
P2860
P304
P356
10.1191/1352458505MS1162OA
P577
2005-06-01T00:00:00Z